Advocates are celebrating a recent U.S. federal decision by HHS recommending that all newborns be screened for Duchenne ...

As 2025 draws to a close, columnist Shalom Lim looks back at the highs and lows he's experienced this year while living with ...

The FDA has granted rare pediatric disease designation to (Z)-Endoxifen as a potential treatment for Duchenne muscular ...

During this season of hope, columnist Robin Stemple shares his wishes for both the disability community and himself.

Experimental therapy deramiocel outperformed a placebo at improving measures of arm and heart health in people with DMD in a ...

Columnist Patrick Moeschen argues that we all should focus more on finding the right words to accurately describe living with ...

Columnist Betty Vertin is planning a holiday season this year that will let her sons with DMD better enjoy their time with family and friends.

Dyne Therapeutics, citing trial data, said it will ask the FDA to approve DYNE-251, its therapy for DMD amenable to exon 51 skipping.

A regimen of three immune-suppressing medications may improve the effectiveness of gene therapy for people with Duchenne muscular dystrophy (DMD), allowing patients to receive treatment more than once ...

Upsher-Smith Laboratories is launching a new corticosteroid treatment for people with Duchenne muscular dystrophy (DMD) in the U.S. ages 5 and older. The therapy, branded Kymbee, is an oral tablet ...